Portola: My Investment Thinking After the Sharp Price Drop (PTLA, Buy, $14.85)Full Year Sales of Andexxa were Impressive but there was a Troubling Drop in Sequential Sales in US in 4Q,… Portola: Detailed Spreadsheet Projecting Sales and Earnings Through 4Q, 2021 (PTLA, Buy, $28.00)Key Points: The sales model presented in this report projects sales for Portola of $119, $264 and $402 million for… Portola: Andexxa Looks to be a Blockbuster (PTLA, $30.00, Buy)Overview The investment story for Portola is virtually 100% based on the sales ramp for Andexxa. Skepticism and/ or uncertainty have… Portola: Andexxa Sales in 1Q, 2019 Were Encouraging and Yet the Stock HasTraded Down (PTLA, Buy, $30.16)Overview of 1Q, 2019 Results I was shocked to see Portola trading down about $5.00 in following the release of 1Q,… Ondexxya Receives Conditional EU Approval as Expected (PTLA, Buy, $36.44)Portola Pharmaceuticals announced last Friday that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa). In the US,… Portola: Detailed Update on Exciting 2019 Outlook (PTLA, Buy, $33.35)
Key The outlook for Portola’s stock price in 2019 and 2020 Portola: NEJM Report on Positive Results in ANNEXA-4 Study is a Significant Positive (PTLA, Buy, $28.89)Overview This report focuses narrowly on the New Portola: Tidbits from Presentation at JP Morgan Healthcare Conference (PTLA, Buy, $21.96)
Investment Thesis in Andexxa is the only approved product for treating severe bleeds (sometimes Portola: Approval of Gen 2 Manufacturing Process for AndexXa is a Significant Positive (PTLA, Buy, $18.75)
Portola received approval for the Prior Approval Supplement Portola Pharmaceuticals: 2019 Is All About the Sales Trajectory of AndexXa (PTLA, $15.46, Buy)
Investment With the disappointing launch of Bevyexxa, almost all of the market value of Portola is based on AndexXa which was… Portola: Critical Upcoming Catalysts Have the Potential to Cause a Sharp Upward Move in the Stock (PTLA, Buy, $29.19)Investor focus is totally on Andexxa at this point in time as the disappointing 2Q, 2018 sales results for Bevyxxa… Portola: Reiteration of Buy Recommendation (PTLA, Buy, S27.46)Introduction This is the latest in a series of updates on Portola and is prompted by information presented in the second… Portola: Update and Reiteration of Buy Recommendation (PTLA, Buy, $39.31)Investment Thesis in Brief This report is based on presentations by management at recent brokerage conferences. It is an update and… Portola: Approval of AndexXa is a Major Positive (PTLA, Buy, $41.19)Investment Opinion Based on assumptions made in this report, I estimate that AndexXa could be valued by investors at $114 to… Portola: Why I Think that AndexXa is Likely to be Approved (PTLA, Buy, $36.44)Key Observations and Conclusions I believe there is a very strong possibility that AndexXa will be approved on its PDUFA… Portola: Uncertainty on AndexXa Approval Leads to 30% Decline in Stock Price (PTLA, Buy, $31.16)Major New Uncertainty for AndexXa The fourth quarter conference call produced alarming information about the FDA review of AndexXa. This drug… Portola Announces a Delay in PDUFA Date for AndexXa (PTLA, Buy, $54.86)Portola announced after the close on December 22, 2017 that the FDA will extend its review of AndexXa (andexanet alfa)… Portola: US Launch of Bevyexxa Is Scheduled for Early January 2018 (PTLA, Buy, $50.03)Portola Pharmaceuticals announced today that the FDA has given the go-ahead for the commercial launch of Bevyxxa (betrixaban). This drug… Portola: Management Guides to a Highly Probable US Launch of Bevyexxa in the December to February Timeframe (PTLA, Buy, $50.52)Perspective on Stock Price Behavior I began coverage of Portola with a Buy in a May 4, 2017 report at… Portola: Reiterating Buy and Refuting Recent Negative Blog by Adam F-stein (PTLA, Buy, $54.12)Introduction Adam F-stein wrote an article on Portola on September 19, 2017 with the headline “Commercial launch of Portola’s new blood… Portola: September 4 Conference Call Provides Update on Potential Launch Date for Bevyxxa and Announces Price (PTLA, Buy, $57.29)Investment Overview Following approval of Bevyxxa, Portola stated that it expected to launch in the US in the September to November… Portola Pharmaceuticals: AndexXa BLA Resubmitted; Reiterating Buy (PTLA, $61.41, Buy)Investment Thesis Portola issued a press release on August 3, 2017 that reported it had just resubmitted the BLA for AndexXa,… Portola Pharmaceuticals: Betrixaban Approval Triggers Big Stock Move-Now What Do We Do? (PTLA, Buy, $55.42)Investment Thesis There was considerable uncertainty as to whether the FDA would approve betrixaban so that the approval caused a sharp… Portola: Reiterating Buy Prior to June 24th PDUFA Date for Betrixaban (PTLA, Buy, $39.35)Portola has two drugs in late stage development that I believe are likely to be approved in 2017 or early… Portola Pharmaceuticals: Initiating Coverage with a Buy (PTLA, $40.05) Overview of Report |